Quick Answer:
- The Cicada (BA.3.2) COVID variant carries over 70 spike mutations, causing distinct early symptoms such as severe throat pain, intense night sweats, and digestive upset.
- While highly transmissible, evidence indicates it carries a low additional public health risk for severe disease compared to earlier Omicron subvariants.
- Early diagnosis using standard antigen tests and targeted symptom monitoring can prevent severe complications such as dehydration and secondary sinus or lung infections.
EMERGENCY WARNING: Seek immediate emergency medical care if you or a family member experience severe shortness of breath, persistent chest pain or pressure, new confusion, pale or blue-tinted lips/skin, or an inability to stay awake. Call 911 or visit the nearest emergency room without delay.
Understanding the Cicada BA.3.2 Subvariant
The SARS-CoV-2 virus continues to mutate as it moves through human populations. In recent months, public health agencies including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) began monitoring a heavily mutated Omicron offshoot known as BA.3.2, informally named the Cicada variant.
Why Is It Called the “Cicada” Variant?
The nickname “Cicada” refers to the biological behavior of cicada insects, which remain dormant underground for long periods before emerging all at once. In a similar way, the BA.3 lineage was an early branch of Omicron that largely vanished in 2022. Health researchers believe BA.3.2 evolved quietly over an extended period—likely inside a chronically infected individual—accumulating more than 70 spike protein mutations before re-emerging in global surveillance networks.
Is BA.3.2 More Severe?
Although BA.3.2 looks significantly different on paper due to its large number of genetic changes, surveillance data from global health authorities indicates that it does not cause more severe illness than other circulating Omicron strains. However, its high number of mutations allows it to slip past some antibody defenses built from older infections or earlier vaccines, making reinfections possible.
Recognized Cicada BA.3.2 COVID Variant Symptoms
The symptoms of the Cicada BA.3.2 variant overlap significantly with traditional COVID-19 manifestations, but clinicians have identified specific presentation patterns that distinguish it during the early days of illness.
Primary Early Symptoms
- Severe Throat Irritation: Patients frequently report a raw, painful throat that feels significantly sharper or more uncomfortable than a mild seasonal cold tickle.
- Profuse Night Sweats: Soaking night sweats—a hallmark feature seen in specific Omicron offshoots—are frequently reported even before a high fever develops.
- Gastrointestinal Symptoms: Nausea, abdominal discomfort, and watery diarrhea are common early signs that are easily mistaken for food poisoning or stomach flu.
- Persistent Dry Cough: A frequent, hacking cough often starts shortly after throat irritation begins.
- Overwhelming Fatigue: Sudden physical exhaustion and body aches make simple daily activities feel extremely difficult.
Additional Upper Respiratory and Systemic Symptoms
- Headache and sinus congestion.
- Low-grade to moderate fever.
- Transient loss or change in taste and smell (less common with BA.3.2 than original 2020 strains, but still possible).
- Mild brain fog and difficulty concentrating.
Unique Clinical Takeaways
To help patients, caregivers, and primary care providers navigate this strain, three major clinical insights stand out from early field reports:
1. Biphasic Presentation and Dehydration Risk
The Cicada BA.3.2 variant often presents with a distinct “biphasic” symptom curve. Patients may initially experience localized gastrointestinal symptoms (diarrhea, nausea) combined with severe night sweats before traditional cough and nasal congestion manifest 48 hours later. Because fluid loss occurs through both sweating and stool, dehydration occurs much faster than with standard respiratory viruses. Continuous oral rehydration solutions should be started at the first sign of night sweats or loose stools.
2. High Rate of “False Negative” Early Home Antigen Tests
Due to the unique mutation density in the BA.3.2 spike protein and high initial viral replication in the lower throat/gastrointestinal tract, rapid home nasal swabs frequently yield false negatives on days 1 and 2 of symptom onset. If you test negative during early symptoms, continue isolating and repeat the rapid antigen test 48 hours later, or request a laboratory PCR test for definitive confirmation.
3. Vulnerability to Secondary Sinus and Respiratory Bacterial Superinfections
Severe upper airway mucosal inflammation caused by BA.3.2 can disrupt natural ciliary clearing mechanisms in the nose and bronchial tubes. Caregivers should monitor patients closely: if initial COVID symptoms seem to improve after 4 to 5 days but suddenly rebound with thick yellow-green discharge, facial pressure, or a spike in fever, consult a healthcare provider to evaluate for a secondary bacterial sinus or chest infection.
Diagnosis, Care, and Prevention Strategies
Testing and Home Management
- At-Home Isolation: Stay home and isolate from housemates if you develop respiratory or stomach symptoms.
- Supportive Care: Get plenty of bed rest and drink electrolyte-balanced fluids. Over-the-counter pain relievers and fever reducers like acetaminophen or ibuprofen can help manage body aches.
- Paxlovid and Antivirals: High-risk patients—including older adults and immunocompromised individuals—should contact their doctor within 5 days of symptom onset to determine eligibility for oral antiviral prescription therapies.
Prevention Measures
Updated COVID-19 vaccines targeting Omicron lineages continue to provide crucial protection against hospitalization and severe outcomes. Additional daily preventive strategies include:
- Wearing well-fitting N95 or KN95 respirators in crowded or poorly ventilated indoor spaces.
- Improving indoor air movement by opening windows or running HEPA air filters.
- Practicing regular hand hygiene with soap and water or alcohol-based sanitizer.
Frequently Asked Questions (FAQs)
Most individuals with mild to moderate BA.3.2 infections begin feeling better within 7 to 10 days, though mild fatigue and a dry cough can persist for two weeks or longer.
Yes, rapid antigen tests do detect BA.3.2, but because initial viral loads in the nose may take longer to build up, serial testing over 48 hours is recommended if your first test is negative.
Loss of taste or smell can occur with BA.3.2, but it is much less common than it was during the initial 2020 and 2021 strains, with severe sore throat and fatigue being far more predominant.
Updated vaccines targeting Omicron family members continue to offer robust protection against severe disease, hospitalization, and death caused by BA.3.2, even if mild breakthrough infections occur.
Isolation can generally end when the individual has been fever-free for at least 24 hours without fever-reducing medications and their overall symptoms are improving, followed by wearing a mask around others for 5 additional days.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute formal medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition, symptom, or treatment plan. Never disregard professional medical advice or delay seeking care because of something you have read on this website.